首页> 美国卫生研究院文献>Malaria Journal >Comparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine - trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon Ivory Coast and Senegal
【2h】

Comparative study of the efficacy and tolerability of dihydroartemisinin - piperaquine - trimethoprim versus artemether - lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon Ivory Coast and Senegal

机译:双氢青蒿素-哌喹-甲氧苄嘧啶与蒿甲醚-氟美特林治疗喀麦隆象牙海岸和塞内加尔单纯性恶性疟原虫的疗效和耐受性的比较研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundThe ACT recommended by WHO is very effective and well-tolerated. However, these combinations need to be administered for three days, which may limit adherence to treatment.The combination of dihydroartemisinin - piperaquine phosphate - trimethoprim (Artecom®, Odypharm Ltd), which involves treatment over two days, appears to be a good alternative, particularly in malaria-endemic areas. This study intends to compare the efficacy and tolerability of the combination dihydroartemisinin - piperaquine phosphate - trimethoprim (DPT) versus artemether - lumefantrine (AL) in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.
机译:背景世卫组织建议的ACT非常有效且耐受性良好。但是,这些组合需要三天给药,这可能会限制对治疗的依从性。二氢青蒿素-磷酸哌喹-甲氧苄氨嘧啶(Artecom ®,Odypharm Ltd)的组合需要进行两天的治疗,似乎是一个很好的选择,尤其是在疟疾流行地区。这项研究旨在比较二氢青蒿素-磷酸哌喹-甲氧苄氨嘧啶(DPT)与蒿甲醚-lumefantrine(AL)联合治疗喀麦隆,象牙海岸和塞内加尔的单纯性恶性疟原虫的疗效和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号